Management of premenstrual syndrome

Nick Panay

Introduction
The diagnosis and management of premenstrual syndrome (PMS) are reviewed, in particular, the evidence for pharmacological and non-pharmacological treatments. Additionally, this review takes a wider view of the situation with particular emphasis on recent attempts to achieve a global consensus on definitions and management. The development of a consensus and guidelines on the definition and management of PMS is essential to encourage acceptance of this condition by patients, health professionals and regulatory authorities.

Methodology
The Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 48 on Management of Premenstrual Syndrome\(^1\) was used as the starting point for this review. The Cochrane Library (including the Cochrane Database of Systematic Reviews, DARE and EMBASE), TRIP, Medline (1966–2006), Psych INFO (1960–2006), CINHAL (1982–2006) and BNI (1985–2006) were searched. The databases were searched using the relevant MeSH terms, including all subheadings, and this was combined with a keyword search. Search words included ‘premenstrual syndrome’, ‘premenstrual tension’, ‘late luteal phase dysphoric disorder’, ‘premenstrual dysphoric disorder’, ‘PMDD’, ‘PMS’, ‘LLPDD’ and ‘PMT’ and the search was limited to humans and the English language. The National Library for Health and the National Guidelines Clearing House were also searched for relevant guidelines and reviews. Enquiries for relevant information were also made to the pharmaceutical industry and researchers for missing studies and discussion with patient advocacy groups [e.g. the National Association for Premenstrual Syndrome (NAPS)]. A superscript system is also used (refer to Key on page 189) to indicate key facts for each intervention.

Definition
Many women experience mild physical and emotional PMS symptoms that are not particularly troublesome. However, when severe these symptoms can lead to a breakdown in interpersonal relationships and interfere with normal activities. A working definition of PMS is “a condition which manifests with distressing physical, behavioural and psychological symptoms not due to organic or underlying psychiatric disease, which regularly recurs during the luteal phase of each menstrual (ovarian) cycle and which disappears or significantly regresses by the end of menstruation”.\(^2\) The severity of symptoms is judged according to the degree of interference with day-to-day activities and relationships (Table 1). Premenstrual exaggeration or exacerbation of symptoms can also occur, though this is not regarded as the “core” diagnosis. Premenstrual dysphoric disorder (PMDD) is the American Psychiatric Association’s definition of severe PMS in the Diagnostic and Statistics Manual – Version IV.

On a more global scale, the International Society for the Study of Premenstrual Disorders chaired by Professor O’Brien has been working on reaching a consensus on a definition and management of premenstrual disorders.\(^3\) The aim is that the consensus document, currently under development, is eventually incorporated in the World Health Organization’s new International Classification of Diseases (ICD–11).

Aetiology
The precise aetiology of PMS remains unknown but cyclical ovarian activity and the effect of estradiol and progesterone on the neurotransmitters serotonin and gamma-aminobutyric acid appear to be key factors. Absence of PMS before puberty, in pregnancy and after the menopause supports the theory that cyclical ovarian activity is important. Rapidly changing estradiol levels, not only premenstrually but also postnatally and perimenopausally, lead to this triad of hormone-dependent depressors often in the same predisposed individual.\(^4\) Recent work has shown that the risk for PMDD is associated with a genetic variation in ER\(\alpha\) [estrogen receptor (ER) alpha] gene.\(^5\) Haploype analyses of ER\(\alpha\) alpha and beta were performed in 91 women with PMDD and 56 controls. Four single nucleotide polymorphisms (SNPs) of ER\(\alpha\) showed significantly different genotype and allele distributions between patients and controls. However, the investigators pointed to the following limitations of the work thus far:

- The sample sizes were small therefore replication is required.
- Are there protective alleles in controls rather than susceptibility alleles in patients?
- The SNPs did not comprehensively interrogate the genes studied This may be the reason for the lack of association with ER\(\beta\).
- This is undoubtedly a complex genetic disorder. The degree of contribution of ER polymorphisms to the expression of PMDD is uncertain.

Prevalence
The reported prevalence of severe PMS is variable and between 3% and 30%.\(^6,7\) The incidence of severe PMS or PMDD appears to be 5–8%. PMS appears more prevalent in women who are obese, perform less exercise and are of lower academic achievement. There is a lower incidence of PMS in women using hormonal contraception.

Diagnosis
Crucial to the management of PMS is the need to make the correct diagnosis. This cannot be accurately established by retrospective recall. It needs to be made by the prospective logging of symptoms by the patient, ideally over two cycles. A symptom questionnaire that can be filled in online is available on the NAPS website (www.pms.org.uk). Alternatively, a well-established validated questionnaire...
The Daily Record of Severity of Problems (DRSP); Figure 1\textsuperscript{8} can be used to document symptoms – this is particularly important if the patient is entered in a study. The questionnaires should continue to be filled in when treatment has been started to give an objective indication of response to therapy. Typical psychological symptoms include mood swings, irritability, depression and feeling out of control; physical symptoms include breast

![Figure 1](https://jprhc.bmj.com/)

**Figure 1** The Daily Record of Severity of Problems (DRSP).\textsuperscript{8} © Jean Endicott and Wilma Harrison. Figure reproduced with the kind permission of the copyright holders

---

### DAILY RECORD OF SEVERITY OF PROBLEMS

Please print and use as many sheets as you need for at least 2 FULL months of ratings.

Each evening note the degree to which you experienced each of the problems listed below. Put an “x” in the box which corresponds to the severity: 1 - not at all, 2 - minimal, 3 - mild, 4 - moderate, 5 - severe, 6 - extreme.

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Felt depressed, sad, “down,” or “blue” or felt hopeless; or felt worthless or guilty</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Felt anxious, tense, “keyed up” or “on edge”</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>had mood swings (i.e., suddenly feeling sad or tearful) or was sensitive to rejection or feelings were easily hurt</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Felt angry, or irritable</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>had less interest in usual activities (work, school, friends, hobbies)</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Had difficulty concentrating</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Felt lethargic, tired, or fatigued; or had lack of energy</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Had increased appetite or overate; or had cravings for specific foods</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Slept more, took naps, found it hard to get up when intended; or had trouble getting to sleep or staying asleep</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Felt overwhelmed or unable to cope; or felt out of control</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>had breast tenderness, breast swelling, bloated sensation, weight gain, headache, joint or muscle pain, or other physical symptoms</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

© Jean Endicott, MD and Wilma Harrison, MD
Management of PMS

Table 1 Definitions of the different types of premenstrual syndrome from Management of Premenstrual Syndrome.1 © Royal College of Obstetricians and Gynaecologists

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premenstrual syndrome (PMS)</td>
<td>PMS symptoms leading up to menstruation and completely relieved by the end of menstruation.</td>
</tr>
<tr>
<td>Mild</td>
<td>Does not interfere with personal/social and professional life.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Interferes with personal/social and professional life but still able to function and interact, although may be suboptimally.</td>
</tr>
<tr>
<td>Severe</td>
<td>Unable to interact personally/socially/professionally – withdraws from social and professional activities (treatment resistant).</td>
</tr>
<tr>
<td>Premenstrual exaggeration</td>
<td>Background psychopathology, physical or other condition with incomplete relief of symptoms when menstruation ends.</td>
</tr>
<tr>
<td>Premenstrual dysphoric disorder</td>
<td>This is a research criterion, not in general use outside the USA. This definition of severe PMS has been adopted by the American Psychiatric Association.</td>
</tr>
</tbody>
</table>

tenderness, bloating and headaches; behavioural symptoms include reduced visuo-spatial and cognitive ability and an increase in accidents. The psychological symptoms are usually complained of as being the most distressing to the sufferer, particularly their impact on relationships.

**Treatment**

**General principles of treatment**

When managing women with PMS, there are certain principles that should be adhered to. Even though not evidence-based, there is little doubt that reduction of stress for instance is a great help in ameliorating the symptoms. Also, dietary measures such as avoidance of carbohydrate binges and limitation of alcohol and caffeine intake are often of benefit. There are data from non-randomised trials suggesting that exercise improves PMS symptoms.9 However, in cases of moderate to severe PMS, it is important that medical therapy is instituted sooner rather than later to avoid unnecessary suffering. Women with marked underlying psychopathology as well as PMS should be referred to a psychiatrist. Symptom diaries (e.g. the DRSP) should be used to assess the effect of treatment.

**Service delivery**

Primary care should deal with most cases of PMS. Awareness of the condition and training in its management is essential. Ideally, women with severe PMS should be managed by a multidisciplinary team, which might comprise a hospital or community gynaecologist, psychiatrist or psychologist, dietician and counsellor. While such services are rarely provided in any National Health Service (NHS) setting, referral to gynaecologists should be reserved for women who have been fully evaluated as having severe PMS and when simpler forms of therapy have been explored. Where there is multidisciplinary provision of care, this is of benefit both from the diagnostic and therapeutic point of view, giving the ability to offer a broad range of interventions from lifestyle interventions and cognitive behavioural therapy (CBT) to gynaecological interventions.10

**Complementary therapies (CAMs)**

When treating women with PMS, complementary medicines may be of benefit, but clinicians need to consider that data from clinical studies are limited and underpowered. Interactions with conventional medicines should also be considered. The referring clinician retains legal responsibility for the patient’s well being when they refer patients to complementary therapists. It is difficult to assess the true value of most of these therapeutic interventions because they are freely available without prescription or physician recommendation, with little regulation of efficacy or safety. Most are not licensed or registered for treatment of PMS. The Medicines and Healthcare products Regulatory Agency (MHRA) and European regulatory authorities are aiming to rectify the situation by insisting that all complementary therapies are registered by 2011 or withdrawn from sale. This section reviews the recent evidence for some of the evidence-based ‘alternative’ interventions that have been used to treat PMS. Treatments have been selected where reasonable efficacy data exist [randomised controlled trial (RCT) data if possible].

**Vitamin B6**

Vitamin B6 is often used to treat PMS without clear evidence of its efficacy.11 The recommended dietary allowance for vitamin B6 is around 2.0 mg/day and deficiency of vitamin B6 is rare. Due to unproven efficacy of vitamin B6 in treating PMS, a systematic review of published and unpublished randomised placebo-controlled trials of effectiveness of vitamin B6 in the management of PMS was undertaken.12 Nine published trials representing 940 patients were reviewed. The main outcome measure was an improvement in overall premenstrual symptoms. The overall methodology of the trials identified was of poor quality, with none of the trials justifying patient numbers with a power calculation. The odds ratio (OR) in favour of vitamin B6 relative to placebo for an improvement in overall PMS was 2.32 (95% CI 1.95–2.54). No conclusive evidence of vitamin B6 toxicity was reported and there was no dose-related response to treatment. There is no rationale for giving daily doses of vitamin B6 in excess of 100 mg, especially following the recommendation from the Department of Health and the Medicine Control Agency in 1999 to restrict the dose of vitamin B6 available generally to 10 mg and to limit the dose sold by a pharmacist to less than 50 mg.

Key to superscripts used in this review

* Few treatments for PMS are actually licensed – the treatments with an asterisk are ones for which sufficient evidence exists for a general practitioner with an interest in women’s health to reasonably prescribe from a medico-legal point of view.

HS Recommended for hospital specialist use.

IE Not recommended, insufficient evidence for efficacy.

IS Not recommended, insufficient evidence for safety.

OTC Over-the-counter medications.
<table>
<thead>
<tr>
<th>Line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Line</td>
<td>Exercise, cognitive behaviour therapy, vitamin B6</td>
</tr>
<tr>
<td></td>
<td>Combined new-generation pill, such as Yasmin®, Cilest® (cyclically or continuously)</td>
</tr>
<tr>
<td></td>
<td>Continuous or luteal phase (Day 15–28) low-dose SSRIs</td>
</tr>
<tr>
<td>Second Line</td>
<td>Estradiol patches (100 μg) + oral progestogen such as duphaston 10 mg (Day 17–28) or Mirena®</td>
</tr>
<tr>
<td></td>
<td>Higher-dose SSRIs continuously or luteal phase</td>
</tr>
<tr>
<td>Third Line</td>
<td>GnRH analogues + add-back HRT (continuous combined estrogen + progestogen or tibolone)</td>
</tr>
<tr>
<td>Fourth Line</td>
<td>Total abdominal hysterectomy and bilateral oophorectomy + HRT (including testosterone)</td>
</tr>
</tbody>
</table>

Figure 2 Algorithm for the management of severe premenstrual syndrome from Management of Premenstrual Syndrome.© Royal College of Obstetricians and Gynaecologists. GnRH, gonadotrophin-releasing hormone; HRT, hormone replacement therapy; SSRIs, selective serotonin reuptake inhibitors. Author’s additional comments: (1) A newer alternative to Yasmin® is Yaz® (see text on page 191). (2) Utrogestan 200 mg is an alternative to duphaston 10 mg.

**Magnesium**

Preliminary studies suggest that magnesium may also be helpful in PMS. A double-blind, placebo-controlled study of 32 women found that magnesium taken from Day 15 of the menstrual cycle to the onset of menstrual flow could significantly improve premenstrual mood changes. Another small, double-blind, preliminary study found that regular use of magnesium could reduce symptoms of PMS-related fluid retention. In this study, 38 women were given magnesium or placebo for 2 months. One small, double-blind study (20 participants) found that magnesium supplementation with vitamin B6 might help prevent menstrual migraine.

**Calcium/Vitamin D**

Studies suggest that blood calcium and vitamin D levels are lower in women with PMS and that calcium supplementation may reduce symptom severity, but it is unknown whether this may prevent the initial development of PMS. In a recent case control study, after adjustment for risk factors, women in the highest quintile of total vitamin D intake (median, 706 IU/day) had a relative risk of 0.59 (95% CI 0.40–0.86) compared with those in the lowest quintile (median, 112 IU/day) (p = 0.01 for trend). The intake of calcium from food sources was also inversely related to PMS; compared with women with a low intake (median, 529 mg/day), participants with the highest intake (median, 1283 mg/day) had a relative risk of 0.70 (95% CI 0.50–0.97) (p = 0.02 for trend). The intake of skimmed or low-fat milk was also associated with a lower risk (p<0.001). A high intake of calcium and vitamin D may therefore reduce the risk of PMS but large-scale clinical trials addressing this issue are required. At present, the only interventional data are from small trials. More data are required to determine efficacy and to optimise regimens.

**Isoflavones (e.g. soy/red clover)**

In a 24-week, double-blind study, 49 women with menstrual migraines received either placebo or a combination supplement containing soy isoflavones, dong quai and black cohosh extracts. The treatment group showed a significantly greater improvement than the placebo group. Recent data from the author’s unit demonstrate a benefit with red clover isoflavones but this is not statistically significantly different to placebo. More data are required before a clear recommendation can be made for isoflavone usage.

**Hypericum perforatum**

Hypericum perforatum (St John’s Wort) is a herbal remedy shown to alleviate mild to moderate depression. However, there has been no clinical investigation on its effectiveness in treating PMS apart from one case report and a small, prospective, open, uncontrolled, observational pilot study. The study investigated whether Hypericum could relieve PMS in a small group of women and tested the methods for conducting future RCTs with this
preparation. Nineteen women with PMS used *Hypericum* tablets for two complete menstrual cycles. There were significant reductions in all outcome measures. The improvement was 51% when the PMS scores were measured between the baseline and the end of the trial, with over two-thirds of women demonstrating at least a 50% decrease in symptom severity. Symptoms which improved the most were emotional and cognitive, which correlates with evidence showing that *Hypericum* has positive effects on mood and that it may moderate brain neurotransmitters.

**Evening primrose** oil

Evening primrose oil, a rich source of gamma linoleic acid, is often used as a treatment for severe PMS. However, the evidence for efficacy in this condition is poor. A prospective, randomised, double-blind and placebo-controlled trial showed that there was no significant difference in the scoring between the active and placebo groups over six cycles. These findings indicate that the improvement experienced by these women with moderate PMS was solely a placebo effect. A meta-analysis of the data has also concluded that evening primrose oil is ineffective in the treatment of severe PMS. Only cyclical mastalgia has been shown to respond to this treatment.

**Medical treatment of PMS**

A suggested treatment algorithm as proposed in the RCOG Green-top Guideline for PMS is shown in Figure 2. Most efficacious treatments for PMS are unlicensed. However, in this situation unlicensed treatments can be justified where a body of evidence and safety exist. The two chief evidence-based medical treatments of moderate to severe PMS are categorised by ovulation suppression and selective serotonin reuptake inhibitors (SSRIs). Ovarian suppression

Although the underlying cause of severe PMS remains unknown, cyclical ovarian activity appears to be an important factor. A logical treatment for severe PMS, therefore, is to suppress ovulation and thus suppress the cyclical endocrine/biochemical changes that cause the distressing symptoms. A number of drugs are capable of performing this function, but they are not without their own side effects, which may influence the efficacy of the treatment or the duration for which they may be given.

**Combined oral contraceptive pill**

Although able to suppress ovulation, and used commonly to improve PMS symptoms, the combined pill was initially not shown to be of benefit in randomised prospective trials. This is probably because it was used with a pill-free week and because the daily progestogen in the second generation pills (e.g. levonorgestrel) regenerated PMS-type symptoms. The relatively new combined oral contraceptive pill (COC) (Yasmin) containing an anti-mineralocorticoid and anti-androgenic progestogen, drosperinone, showed considerable promise in the treatment of severe PMS as it minimised progestogenic side effects with a mild diuretic and anti-androgenic effect. Both observational and small randomised trial data supported efficacy. However, the development of Yasmin has now been succeeded by Yaz, a 20 µg ethinylestradiol/3 mg drosperinone COC but in a 24/4 rather than the conventional 21/7 regimen. The reduction of the hormone-free interval to 4 days reduces the risk of cycle-related symptoms. Two randomised prospective studies trials have demonstrated the efficacy of Yaz over placebo in the treatment of PMDD.

If the “conventional” 21/7 regimen COC is used to treat severe PMS, pill packets should be used back to back (bicycling/tricycling) to avoid the regeneration of cycle-related symptoms during the hormone-free interval. There are data supporting the continuous use of the COC with a break only introduced if breakthrough bleeding occurs.

**Transdermal estradiol**

Oral preparations give insufficient estradiol levels to suppress ovarian activity. A placebo-controlled trial demonstrated that implantable 17β-estradiol combined with cyclical progesterone was effective for the management of physical and psychological symptoms of severe PMS. Administered as a 100 mg implant, this proved to be highly effective when compared with placebo. Implants are less commonly used for PMS since patches have become available, due to their long-lasting effects.

In a randomised, double-blind, placebo-controlled trial of 20 women with crossover at 3 months, transdermal estradiol patches (200 µg) were assessed and found to be highly effective. Women in the active treatment group received two 100 µg estradiol patches followed by placebo and 20 women were treated in reverse order. Significant improvements occurred after changing to active treatment in five of six negative MDQ (Menstrual Distress Questionnaire) symptom clusters and in six of ten PDQ (Prenumetal Distress Questionnaire) symptoms. There was concern that estradiol 200 µg twice weekly was still too high a dose to be used as long-term therapy. A subsequent randomised study showed that 100 µg estradiol patches twice weekly were as effective as 200 µg in reducing symptom levels in severe PMS and this dosage was better tolerated. A recently concluded study from the author’s unit has shown similar benefits of 100 µg patches over placebo with benefits lasting up to 14 months.

Additional barrier or intrauterine methods of contraception should be used when estradiol (patches and implant) are used in PMS as ovulation suppression cannot be guaranteed. There are insufficient data to confirm long-term endometrial and breast safety because long-term randomised prospective safety studies are lacking. However, logic dictates that the hormonal environment is not significantly different to how it would otherwise be in this premenopausal population and observation has not shown any problems over 20 years of usage.

**Progestogen intolerance**

Use of continuous estradiol normally necessitates the addition of cyclical progestogen (10–12 days) to avoid endometrial hyperplasia in women who have a uterus. A study of long-term treatment with the 100 µg dosage using a low dose of cyclical norethisterone acetate (NETA) [1 mg; 10 days/cycle] has shown benefit over placebo over eight cycles with continued improvement in a 6-month extension. Intracutaneous administration of progestogen has the potential to avoid systemic absorption and hence avoid progestogenic effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) as progestogen replacement can maximise efficacy by minimising PMS-like adverse effects. Low systemic levels of levonorgestrel released by the LNG-IUS can initially produce adverse effects (as well as bleeding) in the progestogen-intolerant woman. Despite this, it might still be of advantage to use a LNG-IUS or vaginal progesterone (cyclogest pessaries or crinone gel 8% – not licensed for this indication in this age group) in the progestogen-intolerant woman. In general, when treating women with PMS, treatment with the lowest possible dose of progestogen is recommended to minimise adverse effects.
Danazol**HS**

Cycle suppression may be achieved using danazol, an androgenic steroid. Studies have demonstrated benefit for several symptoms,\(^1\)\(^2\) but due to masculinising side-effects, especially at higher, cycle-suppressing doses, it is not commonly used.

Gonadotrophin-releasing hormone (GnRH) analogues**HS**

Gonadotrophin-releasing hormone (GnRH) analogues have been very successfully employed for many years to suppress ovarian steroid production.\(^3\)\(^4\)\(^5\) Early resort to GnRH therapy for PMS is not recommended due to the potential side effects and cost. Prolonged use should be retained for women with the most severe symptoms. A recent meta-analysis of GnRH analogues has confirmed their efficacy compared with placebo.\(^43\) Seventy-one women on active treatment were identified in seven trials. The overall standardised mean difference (SMD) for all trials was –1.19 (95% CI –1.88 to –0.51) (Cohen criteria: 0.3 small, 0.5 medium, 1.0 large effect) The OR for benefit was 8.66 (95% CI 2.52–30.26). The SMD was –1.43 and OR 13.38 (95% CI 3.9–46.0) if data were taken only from anovulation trials. Efficacy of symptom relief was greater for physical than for behavioural symptoms: physical SMD –1.16 (95% CI –1.53 to –0.79); behavioural SMD –0.68 (95% CI –1.11 to –0.25) but the difference was not significant (p = 0.484).

Data show that symptoms due to the hypo-oestrogenic state can be virtually eliminated and bone mineral density can be maintained by the use of hormone replacement therapy (HRT). Continuous combined therapy or tibolone is preferable to sequential combined therapy in order to minimise the risks of symptom reappearance of PMS-like progestogenic effects.\(^44\)\(^45\) Overall SMD favoured neither GnRH alone or GnRH with add back (95% CI –0.34 to 0.39) demonstrating there is no reversal of the beneficial effect of GnRH when using add-back.\(^46\)

When treating women with PMS with GnRH analogue therapy, treatment should only be continued for 6 months when used alone. Treatment should be combined with HRT to reduce trabecular bone density loss. Women on long-term treatment should have annual measurement of bone mineral density (BMD) (ideally by dual-energy X-ray absorptiometry). Treatment should be stopped if BMD declines significantly in scans performed 1 year apart. General advice about how exercise, diet and smoking affect BMD should be given.

Progestosterone\(^1\)/progestogens\(^1\)

A recent meta-analysis of all published studies for progestogen and progesterone treatment of PMS demonstrated no benefit for treatment.\(^47\) The objective of this systematic review was to evaluate the efficacy of progestosterone and progestogens in the management of PMS. Ten trials of progestosterone therapy (531 women) and four trials of progestogen therapy (378 women) were reviewed. The main outcome measure was a reduction in overall symptoms of PMS. All the trials of progestrone (by both routes of administration) showed no clinically significant difference between progestrone and placebo. For progestogens, the overall SMD for reduction in symptoms showed a slight non-significant difference in favour of progestogen, with the mean difference being –0.036 (95% CI –0.059 to –0.014). The meta-analysis of this systematic review suggested that there was no published evidence to support the use of either exogenous progesterone or progestogens in the management of PMS.

Selective serotonin reuptake inhibitors (SSRIs)**

There is increasing evidence that serotonin may be important in the pathogenesis of PMS. A number of selective serotonin reuptake inhibitors (SSRIs) have been used to treat severe PMS/PMDD. One study consisted of two phases with an initial single-blind washout period followed by a randomised, double-blind, placebo-controlled trial lasting six menstrual cycles. Fluoxetine at 20 or 60 mg was found to significantly reduce symptoms of tension, irritability and dysphoria, as well as physical symptoms compared with placebo, as measured by visual analogue scales (p<0.001).\(^30\) The mean percentage improvement in the luteal phase score from baseline was four to six times greater in the fluoxetine groups than in the placebo group. The adverse effects reported during the trial were dose related, with significantly fewer events occurring in the placebo group and the group receiving 20 mg fluoxetine/day than in the group given 60 mg fluoxetine/day (p<0.001). There are also data suggesting improvement of physical symptoms with SSRIs, though this is probably due to the improved perception rather than genuine reduction in symptom severity.\(^51\) A meta-analysis of all available RCTs involving SSRIs used in PMS confirmed superior efficacy compared with placebo.\(^52\)

The Commission on Human Medicines endorses the view that SSRIs are effective medicines in the treatment of depression and anxiety conditions and that the balance of risks and benefits in adults remains positive in their licensed indications. Prescribing should be restricted to those health professionals who have a particular expertise in this area.

There now exists a wealth of data from other RCTs for the treatment of severe PMS with most types of SSRIs. Randomised studies have now shown that half-cycle SSRIs...
treatment is as efficacious as continuous administration. A randomised, double-blind study compared the responses to luteal phase or full-cycle dosing of sertraline in 31 women fulfilling criteria for severe PMS who completed a preceding double-blind, short-term treatment trial that lasted three menstrual cycles. The results showed that the total PMS scores were lower in the luteal-phase dosing group in each of the three treatment months but the differences were not statistically significant from full-cycle dosing group. Further analysis of each of the symptoms showed significant differences (p<0.05) in favour of luteal-phase dosing for mood swings, nervous tension, feeling out of control and confusion.53 There are also data to suggest that luteal-phase dosing improves symptoms that continue into the post-menstrual phase.54

The importance of this is that patients are less likely to develop dependence on this regimen, benefit is immediate and patients are more likely to accept the treatment as it can be regarded as being different to the regimens used for psychiatric disorders. In the author’s opinion, the optimum regimens for PMS are half-cycle citralopram or escitalopram, 20 mg per day from Day 15 to Day 28 of the cycle. This regimen appears to be effective even in women whose previous SSRI treatment has failed.55 Severe PMS also improves significantly with either luteal-phase or symptom-onset dosing of escitalopram with good tolerability.56 SSRIs/SNRIs (serotonin-norepinephrine reuptake inhibitors) should be considered one of the first-line pharmaceutical management options in severe PMS.

Cognitive behavioural therapy (CBT) A recent study examined the relative effectiveness of fluoxetine (20 mg daily) and CBT (10 sessions), and combined therapy (fluoxetine plus CBT) in women with PMDD.57 This was a randomised treatment trial lasting 6 months; follow-up was undertaken 1 year post-treatment. Significant improvement occurred in all three treatment groups after 6 months of treatment. Fluoxetine was associated with a more rapid improvement but, at follow-up, CBT was associated with better maintenance of treatment effects compared with fluoxetine. There appeared to be no additional benefit of combining the treatments and no difference in efficacy between the treatment groups. A clinical psychology service should be available for women with PMS, ideally as part of the multidisciplinary team.

Conclusions

PMS continues to be poorly understood and in many cases inadequately managed. It can be the cause of considerable morbidity and at times even mortality. It is imperative that a consensus on definition is reached globally and that properly conducted research continues to be funded. It is only through this work that clinicians will be able to practise in a truly evidence-based way to effectively treat this condition.

The alternatives to traditional therapy, such as agnus castus, red clover and St John’s Wort, are showing promising results in RCTs but more data are needed. The data on natural progesterone remain controversial, although many women appear to derive considerable benefit from being on this preparation. Progestogens should not be used as they are very good at reproducing the symptoms of PMS. The more established therapies for which RCT data exist are the newer combined pills (especially Yaz) containing progestogens other than norethisterone and levonorgestrel, transdermal oestradiol, SSRIs and the GnRH analogues.58,59 Hysterectomy with bilateral salpingo-oophorectomy and adequate HRT remains an option for the severely afflicted woman whose family is complete and who has not responded fully to the other therapies.

Statements on funding and competing interests

Funding

None identified.

Competing interests

The author has received honoraria for speaking and advising a number of pharmaceutical companies whose products are mentioned in this review and has also conducted sponsored research with some of these products.

References

19 Thys-Jacobs S, Starkey P, Bernstein D, Tian J, Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179: 444–452.
20 Burke SE, Olson RD, Cusack BJ, Randomized, controlled trial of phytoestrogens in the prophylactic treatment of menstrual

Further reading/information
3 National Association for Premenstrual Syndrome (NAPS). Advice for sufferers and health professionals. Website: www.pms.org.uk.